Articles From: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome to Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT


ArQule, Inc. (NASDAQ: ARQL) today announced an agreement with the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) providing for the clinical development of ARQ 092, an orally available, selective small molecule inhibitor of AKT, in Proteus syndrome, a rare disease characterized by overgrowth of the skeleton, skin, adipose tissue and central nervous system.
Sign-up for ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome investment picks
ArQule, Inc. (Nasdaq: ARQL) today announced that eight presentations of clinical and pre-clinical data on three early clinical-stage product candidates will take place during the 26 th EORTC-NCI-AACR Symposium to be held November 18-21, 2014 in Barcelona, Spain.
Sign-up for ArQule Announces Data Presentations with Pipeline Products to Be Featured at 26th EORTC-NCI-AACR Symposium investment picks
ArQule, Inc. (NASDAQ: ARQL) today announced positive top-line results from a randomized, double-blind, placebo-controlled Phase 2 clinical trial of tivantinib as a single agent in metastatic prostate cancer.
Sign-up for ArQule Announces Positive Top-Line Results of NIH-Sponsored Phase 2 Trial of Tivantinib in Prostate Cancer investment picks
ArQule, Inc. (NASDAQ: ARQL) today reported its results of operations for the fiscal quarter and nine months ended September 30, 2014.
Sign-up for ArQule Announces Third Quarter Fiscal 2014 Results investment picks
ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial results for the third quarter of 2014 on Monday, November 10, 2014 at 7:00 a.m. Eastern Time.
Sign-up for ArQule to Report Third Quarter 2014 Financial Results on November 10, 2014 investment picks
- Final results from binimetinib Phase 2 in NRAS melanoma confirmed prior Progression Free Survival result and demonstrated encouraging Overall Survival- -Most frequently observed adverse events consistent with MEK inhibitor class- -Selumetinib demonstrated tolerability with multiple first-line NSCLC chemotherapy doublets, and dose exploration is ongoing- BOULDER, Colo.
Sign-up for Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2015 investment picks
2014/12/3
- Array to receive up to $85 million upfront payment from Novartis - - Novartis to conduct and/or substantially fund all ongoing and several planned clinical studies, including COLUMBUS, NEMO and MILO - - Agreement subject to Novartis-GSK transaction close - - Conference call to discuss transaction on Thursday, December 4, 2014 at 9:00 a.m. Eastern Time - BOULDER, Colo.
Sign-up for Array To Regain Worldwide Rights To Binimetinib investment picks
SUWANEE, Ga.
Sign-up for ARRIS To Present At 2014 UBS Global Technology Conference investment picks
SUWANEE, Ga.
Sign-up for ARRIS To Present At The 17th Annual Needham Growth Conference investment picks
Arrow Electronics, Inc. (NYSE:ARW) today announced it has added CenturyLink Cloud to its cloud service portfolio and the ArrowSphere cloud marketplace that is available to solution providers, managed service providers, and independent software vendors in the United States and Canada.
Sign-up for Arrow Adds CenturyLink Cloud to the ArrowSphere Cloud Services Marketplace investment picks
Arrow Electronics, Inc. (NYSE:ARW) announced today the approval by the company’s Board of Directors of the repurchase of up to an additional $200 million of common stock through a share repurchase program.
Sign-up for Arrow Electronics Announces Additional $200 Million Share Repurchase Program investment picks
Arrow Electronics (NYSE: ARW) today announced that it has been positioned by Gartner, Inc. in the “Leaders” quadrant of the “Magic Quadrant for IT Asset Disposition, Worldwide.” 1 “For us, it is extremely gratifying to see the market recognition and external validation that the Gartner Magic Quadrant for IT Asset Disposition, Worldwide provides,” said Mark Majeske, president of Arrow’s global reverse logistics business.
Sign-up for Arrow Electronics Positioned in the “Leaders” Quadrant of the Magic Quadrant for IT Asset Disposition, Worldwide investment picks
Arrow Electronics, Inc. (NYSE:ARW) today reported third-quarter 2014 net income of $146.9 million, or $1.47 per share on a diluted basis, compared with net income of $96.8 million, or $.95 per share on a diluted basis in the third quarter of 2013.
Sign-up for Arrow Electronics Reports Third-Quarter Non-GAAP Earnings Per Share of $1.40 investment picks
Arrow Electronics Inc. (NYSE:ARW) today announced the SAM Project was awarded a 2014 Institution of Engineering and Technology (IET) Award in the Intelligent Systems category during a recent ceremony in London.
Sign-up for Arrow Electronics SAM Project Wins 2014 Institution of Engineering and Technology Award investment picks
Arrow Electronics, Inc. (NYSE: ARW), today announced that it now carries the complete RF and microwave portfolio from Analog Devices, Inc. (ADI), including the Hittite Microwave products.
Sign-up for Arrow Electronics to Offer Hittite Microwave Product Line investment picks
Arrow Electronics, Inc. (NYSE:ARW) announced that Paul J.
Sign-up for Arrow Electronics to Present at the UBS Global Technology Conference investment picks
2014/10/23
GLENS FALLS, N.Y. , Oct.
Sign-up for Arrow Financial Corporation Announces $5 Million Stock Repurchase Program investment picks
2015/1/21
-- Net income for 2014 reached a new record high of $23.4 million.
Sign-up for Arrow Reports Record Earnings for 2014; Over 11% Loan Growth investment picks
Arrow Electronics, Inc. (NYSE: ARW) today announced it has received the Global Sales Leadership Distributor award from Trend Micro, a global leader in security software and solutions.
Sign-up for Arrow Wins Trend Micro Global Sales Leadership Award investment picks
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate, ARC-AAT, for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
Sign-up for Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ArQule Announces Collaboration with NIH for Clinical Development of ARQ 092 in Proteus Syndrome to Arrowhead Files for Regulatory Permission to Begin Phase 1 Trial of RNAi Therapeutic ARC-AAT
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent